Pituitary & hypothalamus

Prevalence and evolution of hypertension in a large Iberian cohort of patients with acromegaly

PituitaryPublished Retrospective cohort study

Authors' conclusion

At the time of acromegaly diagnosis up to 50% of patients have hypertension, and around 15% of them experience hypertension remission after pituitary surgery. The probability of remission is higher in patients with milder baseline hypertension and higher IGF-1 levels and in those achieving a greater postoperative decrease of GH and IGF-1.

Study context

Population
Patients with acromegaly surveilled at 25 tertiary hospitals in Spain and Portugal
Participants
434 patients
Exposure
Patients with vs without hypertension at acromegaly diagnosis
  • Hypertensionn = 209
  • No hypertensionn = 225reference
Outcome
Prevalence of hypertension at acromegaly diagnosis
Follow-up
Acromegaly diagnosis
Methodological detailsmulticenter, 25 tertiary hospitals
  • Multicenter
  • 25 tertiary hospitals

Main finding

As reported in the abstract

Hypertension at acromegaly diagnosis

Prevalence of hypertension

209

48.2%

Observational data: associations, not effects.

Further findings

Blood pressure (BP) change 3 months after pituitary surgery

ΔSBP
- 5.0mmHg (95%CI −2.37 to −7.61)
ΔDBP
- 2.2mmHg (95% CI −0.66 to −3.75)

Incident hypertension in initially normotensive patients · median follow-up 8.4 years [IQR 4.8-12.8]

Developed hypertension
16% (n = 35/218)

Hypertension remission in hypertensive patients · median follow-up 8.4 years [IQR 4.8-12.8]

Achieved hypertension remission
14.1% (n = 27/192)
Remission more likely with fewer antihypertensive drugs and higher IGF-1 at diagnosis, and greater postoperative decrease in GH and IGF-1

Original publication

Prevalence and evolution of hypertension in a large Iberian cohort of patients with acromegaly. Pituitary. Published 25 October 2025. doi:10.1007/s11102-025-01586-1

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.